FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Pfizer/OPKO Complete Response on Growth Hormone

[ Price : $8.95]

FDA issues Pfizer and OPKO Health a complete response letter for their BLA for somatrogon, an investigational once-weekly long-act...

FDA Launches REMS Public Dashboard

[ Price : $8.95]

FDA launches a REMS Public Dashboard to improve data access and transparency.

Praise, Suggestions for Hearing Aid Rule

[ Price : $8.95]

Five stakeholders give FDA their recommendations for changes to its proposed rule to establish a regulatory category for OTC heari...

Proposal to Classify Certain Antigen Devices in Class 2

[ Price : $8.95]

Federal Register notice: FDA seeks comments on its proposal to classify human leukocyte antigen, human platelet antigen, and human...

Class 2 for Retinal Diagnostic Software Devices

[ Price : $8.95]

Federal Register notice: FDA classifies retinal diagnostic software devices into Class 2 (special controls).

Improve Accelerated Approval Process: Califf

[ Price : $8.95]

FDA commissioner nominee Robert Califf says ways must be found to speed confirmatory trials for drugs given accelerated approval.

FDA Hold on Dyne Muscular Dystrophy IND

[ Price : $8.95]

FDA places a clinical hold on Dyne Therapeutics IND for a trial of Dyne-251 to treat Duchenne muscular dystrophy.

Aurobino Pharma Gets 2nd Warning Letter in 15 months

[ Price : $8.95]

FDA sends Aurobindo Pharma a Warning Letter over GMP deficiencies cited 8/2021 at its Hyderabad, India-based Unit 1 active pharmac...

Mylan Recalls One Batch of Semglee Insulin

[ Price : $8.95]

Mylan Pharmaceuticals recalls one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml, 3mL prefill...

Sensydia Breakthrough Status for Cardiac Biosensor Monitor

[ Price : $8.95]

FDA grants Sensydia a breakthrough device designation for its Cardiac Performance System that measures critical cardiac function.